AAV BAG3 Gene Therapy for Cardiomyopathy Gene Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for BAG3-related cardiomyopathies, such as dilated cardiomyopathy, are ineffective, and there is a need for improved therapeutic options to address the downregulation of the BAG3 gene associated with cardiac dysfunction and heart failure.
Innovation Solution
Gene therapy vectors, particularly AAV vectors, are used to deliver a polynucleotide encoding BAG3 or functional variants, utilizing heterologous promoters like MHCK7, hTNNT2, HSP70, UBC, or CAG promoters to restore BAG3 expression in subjects with BAG3 mutations or downregulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmacological therapies and cardiac ablation are used, then treatment is provided, but treatment effectiveness is insufficient
Solution Approach 1:
The patent replaces conventional pharmacological therapies and cardiac ablation with gene therapy using AAV vectors to deliver functional BAG3 gene. This substitution of treatment mechanism addresses the insufficiency of current therapies by directly correcting the genetic defect rather than providing symptomatic relief, thereby improving both treatment effectiveness and therapeutic outcome.
Solution Approach 2:
The patent changes the fundamental parameter of treatment from chemical/pharmacological intervention to genetic intervention. By introducing functional BAG3 gene via AAV vector, the treatment fundamentally alters the disease mechanism at the genetic level, transforming ineffective symptomatic treatment into curative disease-modifying therapy.
2Reliability
If BAG3 expression is restored through gene therapy, then protein quality control and sarcomere integrity are improved, but vector delivery and expression control complexity increases
Solution Approach 1:
The patent uses AAV vector as an intermediary carrier to deliver the functional BAG3 gene to cardiac cells. This vector-mediated approach simplifies the overall system by providing a well-characterized, safe, and efficient delivery mechanism that bypasses the complexity of direct gene insertion or other advanced delivery systems, while still achieving reliable protein restoration.
Solution Approach 2:
The patent employs a universal AAV vector platform that can be adapted for different promoter sequences (e.g., cardiac-specific promoters like MHCK7, hTNNT2, HSP70, UBC, or CAG promoters) to target various cell types and conditions. This multi-functional vector system reduces complexity by using a single versatile delivery platform rather than requiring separate specialized delivery systems for different applications.
Data Source
AI summary
Provided herein is a gene therapy for BAG3 (B-cell Lymphoma 2-Associated Anthanogene 3), e.g., using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter, a cardiac troponin T (hTNNT2) promoter, a heat shock protein 70 (HSP70) promoter, or a ubiquitin C (UBC) promoter. The capsid may be an AAVrh.74 or AAV9 capsid or a functional variant thereof. In certain embodiments, the capsid is an AAVrh.74 capsid or functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the AAV vector, and other compositions and methods.